TAP is a partnership filled with opportunity. It's how we began and it's how we operate.

We are a portfolio company with multiple compounds in clinical development. Our competencies in basic and developmental science include toxicology, pathology, pharmacology, pharmacokinetics, metabolism, bioanalytic science, pharmaceutical development, chemical synthesis and analytical science.

Our sales force is known within the industry for its excellence. In a 2004-2005 ranking of 97 sales forces, gastroenterologists ranked TAP first on product knowledge and first overall. OB/GYNs listed TAP in their top ten most-preferred sales forces, as did urologists.

We shepherd partnership compounds through the entire supply chain - with manufacturing and packaging flexibility; with effective physician access and timely physician-level sales reporting and territory-level analysis; with dedicated specialty marketing, specialty sales forces and specialty distribution; with up-to-date understanding of managed care and critical reimbursement issues; and with dynamic marketing.

We excel at managed care. TAP is recognized as a Top 10 company by leading managed care organizations. We have extensive managed care contracting and pricing experience with both oral and injectible products, and we possess expert knowledge of the Medicare Modernization Act.

We are the 14th largest pharmaceutical company. We have more than 3,000 employees. Our expertise is in drug development, quality assurance, sales and marketing. We are focused on the core areas of gastroenterology, metabolic disorders, urology and women's health.

We are known for our market-leading products. Prevacid (lansoprazole), is a proton pump inhibitor with the most indications and most administration options of any medication in the category. Based on third-year sales, Prevacid is the sixth largest launch in pharmaceutical history.

Lupron Depot (leuprolide acetate for depot suspension) is a treatment for advanced prostate cancer, endometriosis and central precocious puberty. Lupron Injection (leuprolide acetate) was the first new hormonal treatment for prostate cancer in 40 years when it launched and today Lupron Depot is the leader in its class of leutenizing hormone-releasing hormone (LH-RH) analogs.

If you have a partnership idea, we would love to hear from you. Please contact us toll-free in the U.S. at 866-236-1506 or 847-582-6654.